Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Daptomycin is an antibiotic that is affective against many strains of antibiotic resistant
microorganisms. This antibiotic would be appropriate for use in the intensive care unit (ICU)
considering the severity of illness and high risk for infection within this hospital
environment. While in the ICU, patients may develop acute renal failure. Approximately 75% of
ICU patients who develop acute renal failure will require some form of renal replacement
therapy until their kidneys recover. Continuous hemodialysis is becoming one of the most
common forms of dialysis in the ICU as it is a gentle type of dialysis provided over longer
periods of time. The current data demonstrating the ability of continuous hemodialysis to
remove daptomycin from the body is derived from in-vitro trials. The purpose of this trial is
to determine the extent of daptomycin removal from critically ill patients receiving
continuous hemodialysis. Findings from this trial will be used to develop new dosing
recommendations for daptomycin in continuous hemodialysis.